Nanosynex · Ultra-fast Antimicrobial Susceptibility Test for diagnosing antimicrobial resistance to provide personalized antibiotic treatments

Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR.Inappropriate antibiotic use is widespread. In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long. Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours). This will allow physicians to get same-day results (i.e., in less than 5 hours) for AST, a unique feature that will save at least one day of hospitalization per patient and help reducing the spread of resistant bacteria. A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction. Nanosynex Ltd is an Israeli start-up providing health-care systems with a rapid microfluidic diagnostic solution for faster and personalised antibiotic treatment. The company intends to scale up in the European market first, thanks to its strategic partnership with Biosynex, a leading French rapid diagnostic test (RDT) company that has an established distribution network in Europe, Middle East and Africa (60+ countries). Afterwards, Nanosynex will expand internationally. Nanosynex forecast to generates 14.7M€ , and and at EBITDA of 3.4M€ by 2024